ASCO: Clovis CEO defends Rubraca's ovarian cancer win as FDA wants more assurance

ASCO: Clovis CEO defends Rubraca's ovarian cancer win as FDA wants more assurance

Submitted by admin on June 6, 2022 - 9:57am
Source: 
Fierce Pharma
News Tags: 
ASCO 2022
Clovis
Rubraca
ovarian cancer
FDA
Headline: 
ASCO: Clovis CEO defends Rubraca's ovarian cancer win as FDA wants more assurance
snippet: 

In the hopes of catching up with AstraZeneca and GSK, Clovis Oncology recently trotted out a broad trial success that supported bumping up Rubraca in the ovarian cancer treatment order.

Do Not Allow Advertisers to Use My Personal information